Nomura Holdings’s Protagonist Therapeutics PTGX Stock Holding History

Nomura Holdings’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50,000	Closed	-$2.76M	–	2038
2025 Q2	$2.76M	Buy	+50,000	New	+$2.4M	0.01%	749

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Nomura Holdings's PTGX Position: Q2 2026 in Review

Nomura Holdings sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 10,479 shares — an estimated $1.1M sold.

Nomura Holdings first reported a position in PTGX in Q3 2024 and held it in 4 quarters. The position peaked at $1.53M in Q4 2025. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Nomura Holdings reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
Nomura Holdings sold 10,479 Protagonist Therapeutics shares in Q2 2026, an estimated $1.1M.
Nomura Holdings first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 4 quarters.
Nomura Holdings's Protagonist Therapeutics position peaked at $1.53M in Q4 2025.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Nomura Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.